17
2ndNCI-SNMMI Workshop on Targeted Radionuclide Therapy
October 24-25, 2014
National Institute of Health Campus, Building 31, Room 10, Bethesda, MD 20892
Friday, October 24, 2014
8:00 – 8:15 amIntroduction and Opening Remarks
Co-chairs,
Frederic Fahey, DSc, Harvard Medical School
Katherine Zukotynski, MD, University of Toronto
Session One – Lessons Learned
Session Chairs:Richard Wahl, MD, Johns Hopkins University
Ruby F. Meredith, MD, PhD,University of Alabama at Birmingham
8:15-8:40 amRadiochemistry Perspective
Cathy S. Cutler, PhD, University of Missouri
8:40-9:05 am Industry Perspective
Lee Allen, MD, PhD, Spectrum Pharmaceuticals
Rick Satitpunwaycha,PharmD,Spectrum Pharmaceuticals
9:05-9:30 amNuclear Medicine: Lymphoma
Janis O'Malley, MD, University of Alabama at Birmingham
9:30-9:55 amPeptide Receptor Radionuclide Therapy (PRRT) of Neuroendocrine Tumors
Richard Baum, MD,THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging
9:55-10:20 amOncology: Prostate Cancer
Fatima Karzai, MD, National Cancer Institute
10:20-10:40BREAK
Session Two – Opportunities
Session Chairs: Ekaterina Dadachova, PhD,Yeshiva University
Michael R. Zalutsky, PhD,Duke University Medical Center
10:40-11:05 am Targets and Targeting Agents
Janice M. Reichert, PhD, Reichert Biotechnology Consulting LLC
11:05-11:30 am Radiochemistry
Martin Brechbiel PhD, National Cancer Institute
11:30-11:55 am Treatment Planning
Barry Wessels, PhD,Medical Physics and Dosimetry at University Hospitals of Cleveland & AAPM
11:55-12:20 amNuclear Medicine Physician’s Perspective
Steven Mark Larson, MD, FACNM, Memorial Sloan Kettering Cancer Center
LUNCH/ DISCUSSION
Session Three – Hurdles and Incentives
Session Chairs: Aimal Khan Ahmed,MBBS, Bayer HealthCare US
Katherine Zukotynski, MD,University of Toronto
1:00-1:25 pmRegulatory Affairs
Paula M. Jacobs, PhD, National Cancer Institute
1:25 -1:50 pm Industry Perspective
David M. Goldenberg, MD, SCD,Immunomedics Inc. and Center for Molecular Medicine and Immunology
1:50-2:15 pmRadiopharmaceutical Issues
Sally Schwarz, MS, BCNP,Washington University Medical School in St. Louis
2:15-3:15 pmRound Table Discussion
Round Table Chairs:Dr. Ulli Köster, Institut Laue-Langevin
John Valliant, PhD,Centre for Probe Development and Commercialization
Round Table:Aimal Khan Ahmed, MBBS,Bayer HealthCare US
Jehanne Gillo, PhD, Department of Energy
Dr. Cees van Echteld, ABX-CRO
Deepa Narayanan, NCI Small Business Innovation Research
Greg Evans, PhD,NCI Small Business Innovation Research
3:15 -5:30 pm Breakout Session 1: Breast Cancer
Jo Anne Zujewski, MD, National Cancer Institute
Breakout Session 2: Lymphoma/Leukemia
Janis O'Malley, MD, University of Alabama at Birmingham
Breakout Session 3: Lung Cancer/Neuroendocrine Cancer
Giuseppe Giaccone, MD, PhD, Lombardi Comprehensive Cancer Center at Georgetown University
Breakout Session 4: Prostate Cancer
Martin Pomper, MD, PhD,Johns Hopkins University
5:30 pmDay One Adjournment
Saturday, October 25, 2014
8:00-8:15 amReview of Day 1 Progress
Katherine Zukotynski, MD and Frederic Fahey, DSc
8:15-10:15 amSummary Reports from Breakout Groups
Session chairs:Suresh Srivastava, PhD,Brookhaven National Laboratory
Chaitanya Divgi, MD,Columbia University
8:15 – 8:45 amSummary Report Breakout Session 1: Breast Cancer
Stanley Lipkowitz, MD, PhD, National Cancer Institute
8:45 – 9:15 amSummary Report Breakout Session 2: Lymphoma/Leukemia
Jeffery Norenberg, PharmD, PhD, University of New Mexico Health Sciences Center
9:15 – 9:45 amSummary Report Breakout Session 3: Lung Cancer/Neuroendocrine Cancer
Shakun Malik, MD, National Cancer Institute
9:45 – 10:15 amSummary Report Breakout Session 4: Prostate Cancer
Eric M. Rohren, MD, PhD,MD Anderson Cancer Center
10:15-10:30 amBREAK
11:00 – 11:15 amHighlights and Future Directions
Hossein Jadvar, MD, PhD, MPH, MBA, FACNM,University of Southern California
11:15 – 11:30 amConcluding Remarks and Summary
Katherine Zukotynski, MD and Frederic Fahey, DSc